Gyros Protein Technologies introduces Gyrolab Generic Anti-AAV Kit to support gene therapy development Post author: Post published:June 17, 2024 Post category:uncategorized Ready-to-use kit enables detection of binding antibodies against AAV vectors without the need for serotype-specific assays. You Might Also Like Study explores the impact of COVID-19 pandemic among youth and parents across the U.S. Midwest August 3, 2025 Nutrigenomics paves the way for customized diets in lactose intolerance care January 24, 2024 Researchers discover new genetic cause of hereditary optic atrophy October 16, 2025
Study explores the impact of COVID-19 pandemic among youth and parents across the U.S. Midwest August 3, 2025